{
    "clinical_study": {
        "@rank": "94126", 
        "arm_group": {
            "arm_group_label": "LDE225 & Paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)\nPhase I, Part B: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
        }, 
        "brief_summary": {
            "textblock": "The primary aim of this trial is to establish the maximum tolerated dose (MTD) and the\n      recommended phase II dose (RP2D) of LDE225 given in combination with standard doses of\n      paclitaxel in patients with advanced solid tumors. In addition, the preliminary anti-tumor\n      activity of this combination will be assessed, in particular in ovarian cancer."
        }, 
        "brief_title": "LDE225 and Paclitaxel in Solid Tumors", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumor", 
            "Ovarian Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, open label phase I dose-escalation trial of LDE225 administered once\n      daily (OD) with Paclitaxel administered weekly for three weeks (days 1, 8, 15) in 28-day\n      cycles in adult patients with advanced solid tumors that have progressed despite standard\n      therapy.\n\n      The trial will consist of two parts. In Part A (dose escalation following a standard 3+3\n      design), patients with previously treated advanced solid tumors will receive escalating\n      doses of LDE225 in combination with standard Paclitaxel doses, to define the MTD and the\n      RP2D of LED225 OD that can be given in combination with standard doses of Paclitaxel. Once\n      the MTD and RP2D is established in 6 patients, then part B will start.\n\n      Part B is an expansion cohort in 6 patients with advanced platinum-resistant ovarian cancer\n      to further evaluate the safety of the combination and to assess for any preliminary\n      antitumor activity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must give written informed consent before registration.\n\n          -  For Part A: Histologically or cytologically confirmed diagnosis of advanced solid\n             tumors that have progressed despite standard therapy. No more than two prior lines of\n             chemotherapy for advanced disease.\n\n          -  For Part B: Histologically or cytologically confirmed diagnosis of advanced ovarian\n             cancer. Prior chemotherapy must have contained a platinum and a taxane at some point.\n             Any prior taxane therapy must have been administered on a 3-week schedule. A maximum\n             of 2 prior chemotherapy lines for advanced disease will be permitted. Patients must\n             be refractory (PD during chemotherapy) or resistant (PD within 6 months of completing\n             chemotherapy) to their last platinum-containing chemotherapy regimen.\n\n          -  For Part B, patients must have measurable disease according to RECIST v1.1\n             Radiological evaluations to be performed within 4 weeks before registration.\n\n          -  WHO performance status 0-1\n\n          -  Age \u2265 18 years\n\n          -  Hematological values: ANC \u2265 1.5 x 109/L, platelets \u2265 100 x 109/L, Hemoglobin \u2265 100\n             g/L\n\n          -  Adequate hepatic function: bilirubin \u2264 1.5 x ULN, AST and ALT \u2264 2.5 x ULN or \u2264 5.0 x\n             ULN if liver metastases are present\n\n          -  Creatine phosphokinase (CPK) \u2264 ULN\n\n          -  Albumin \u2265 30g/L\n\n          -  Adequate renal function (calculated creatinine clearance > 50 mL/min, according to\n             the formula of Cockcroft-Gault)\n\n          -  Archived tumor tissue must be available.\n\n          -  Women are not breastfeeding.\n\n          -  Women of child-bearing potential are using effective contraception, are not pregnant\n             and agree not to become pregnant during participation in the trial and during the 12\n             months thereafter. They are required to have a negative serum pregnancy test before\n             registration.\n\n          -  Men agree not to father a child during participation in the trial and during 12\n             months thereafter.\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the trial or those who prior to the\n             first dose of combination have not recovered to \u2264 CTCAE Grade 1 from adverse events\n             due to agents administered more than 4 weeks earlier\n\n          -  Symptomatic brain metastases\n\n          -  Prior therapy with a Hedgehog inhibitor\n\n          -  Known or prior hypersensitivity to taxanes or drugs containing Cremophor in spite of\n             premedication\n\n          -  Positive HIV test\n\n          -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test\n\n          -  Impairment of gastrointestinal (GI) function or GI disease (e.g., ulcerative disease,\n             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel\n             resection)\n\n          -  Impaired cardiac function or clinically significant heart disease\n\n          -  Patients who are receiving treatment with medications that are known to be strong\n             inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that\n             cannot be discontinued\n\n          -  Patients who are currently receiving treatment with warfarin sodium (Coumadin)\n\n          -  Patients who are currently receiving immunosuppressive treatment and in whom the\n             treatment cannot be discontinued prior to starting trial drug.\n\n          -  Patients receiving medications that are recognized to cause rhabdomyolysis, such as\n             HMG CoA reductase inhibitors (statins) clofibrate, gemfibrozil, and that cannot be\n             stopped at least 2 weeks prior to the initiation of LDE225 treatment\n\n          -  Patients who have undergone major surgery \u2264 2 weeks prior to starting trial drug or\n             who have not recovered from such therapy\n\n          -  Psychiatric disorder precluding understanding of information on trial related topics,\n             giving informed consent, or interfering with compliance for oral drug intake."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954355", 
            "org_study_id": "SAKK 65/12", 
            "secondary_id": [
                "CLDE225XCH01T", 
                "2013DR1122"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "LDE225 & Paclitaxel", 
                "description": "400, 600 and 800 mg OD", 
                "intervention_name": "LDE225", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LDE225 & Paclitaxel", 
                "description": "80 mg/m2 (days 1, 8, 15)", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "advanced solid tumor", 
            "ovarian cancer", 
            "LDE225", 
            "Paclitaxel", 
            "Hedgehog inhibitor"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "anastasios.stathis@eoc.ch", 
                    "last_name": "Anastasios Stathis, MD", 
                    "phone": "+41 91 811 89 31"
                }, 
                "facility": {
                    "address": {
                        "city": "Bellinzona", 
                        "country": "Switzerland", 
                        "zip": "6500"
                    }, 
                    "name": "Istituto Oncologico della Svizzera Italiana"
                }, 
                "investigator": {
                    "last_name": "Anastasios Stathis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "roger.vonmoos@ksgr.ch", 
                    "last_name": "Roger von Moos, MD, PD", 
                    "phone": "+41 81 256 66 47"
                }, 
                "facility": {
                    "address": {
                        "city": "Chur", 
                        "country": "Switzerland", 
                        "zip": "7000"
                    }, 
                    "name": "Kantonsspital Graub\u00fcnden"
                }, 
                "investigator": {
                    "last_name": "Roger von Moos, MD, PD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "krisztian.homicsko@chuv.ch", 
                    "last_name": "Krisztian Homicsko, MD, PhD", 
                    "phone": "+41 79 556 74 16"
                }, 
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "1011"
                    }, 
                    "name": "Centre Pluridisciplinaire d`Oncologie CHUV"
                }, 
                "investigator": {
                    "last_name": "Krisztian Homicsko, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dagmar.hess@kssg.ch", 
                    "last_name": "Dagmar Hess, MD", 
                    "phone": "+41 71 494 11 11"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "9007"
                    }, 
                    "name": "Kantonsspital St. Gallen"
                }, 
                "investigator": {
                    "last_name": "Dagmar Hess, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "LDE225 in Combination With Paclitaxel in Patients With Advanced Solid Tumors - A Multicenter Phase I Trial", 
        "overall_contact": {
            "email": "milica.enoiu@sakk.ch", 
            "last_name": "Enoiu Milica, PhD", 
            "phone": "+41 31 389 94 61"
        }, 
        "overall_official": [
            {
                "affiliation": "IOSI, Ospedale San Giovanni", 
                "last_name": "Anastasios Stathis, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "IOSI, Ospedale San Giovanni", 
                "last_name": "Cristiana Sessa, Prof Dr med", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Dose limiting toxicities (DLTs) of the combination of LDE225 with paclitaxel in patients with advanced solid tumors", 
            "safety_issue": "Yes", 
            "time_frame": "until up to 4 weeks after start of trial therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954355"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency and severity of adverse events based on the Common Terminology Criteria for Adverse Events V.4.0 (CTCAE).", 
                "safety_issue": "Yes", 
                "time_frame": "expected average 3 months"
            }, 
            {
                "measure": "Objective tumor responses based on RECIST 1.1 criteria.", 
                "safety_issue": "No", 
                "time_frame": "expected average 3 months"
            }
        ], 
        "source": "Swiss Group for Clinical Cancer Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Swiss Group for Clinical Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}